Hazardous or Poisonous Substance – Page 2

FDA Approves Vertex’s Journavx: First Non-Opioid Pain Medication in Decades

6 months ago talkbio0Tagged Acute onset pain, Approved, Journavx, Non-Opioid, Opioids, Pain management, Suzetrigine, United States Food and Drug Administration

Journavx, suzetrigine, non-opioid, acute pain, FDA approval, Vertex Pharmaceuticals, pain management, opioid alternative

Sackler Family and Purdue Pharma Agree to Enhanced $7.4 Billion Opioid Settlement

6 months ago talkbio0Tagged addiction, Agreement, Crisis, multistate, Opioids, Pharma, Purdue, Recovery - action, Sackler family

Sackler family, Purdue Pharma, opioid settlement, $7.4 billion, multistate agreement, opioid crisis, addiction treatment, recovery programs

Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote

6 months ago talkbio0Tagged Antidote, CAR-T, Catalent, decentralized, Duodote, Galapagos, Kindeva, Lymphoma, Non-Hodgkin, Manufacturing, Nerve Agents, NHL, Strategic National Stockpile

Catalent, Galapagos, CAR-T therapy, Decentralized manufacturing, Non-Hodgkin lymphoma (NHL), Kindeva Drug Delivery, DuoDote, Nerve agent antidote, Strategic National Stockpile

Medtronic’s PillCam Genius SB Completes First Patient Procedure for GI Diagnostics

7 months ago talkbio0Tagged antimony, Capsule Endoscopy, Diagnostics, gastroenterology (field), Ingestion, Medtronic, PillCam Genius, Telemedicine

Medtronic, PillCam Genius SB, Capsule Endoscopy, GI Diagnostics, At-Home Ingestion, Telehealth

Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens

8 months ago talkbio0Tagged Biotechnology, Builder, Hallucinogens, Laboratory test finding, mental health, Negev, neuroplastogens, non-hallucinogenic, psychedelic therapies

Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder

Cybin’s Psychedelic Drug CYB003 Demonstrates Sustained Efficacy in Reducing Depression Symptoms Over 12 Months

8 months ago talkbio0Tagged Analog, CYB003, Effectiveness, Hallucinogens, MDD, Mental Depression, Sustained, Symptom reduction, Unipolar Depression

CYB003, psychedelic drug, depression treatment, sustained efficacy, 12-month symptom reduction, major depressive disorder (MDD), psilocin analog.

Cybin’s Psychedelic Breakthroughs: Advancing Mental Health Treatments

8 months ago talkbio0Tagged Breakthrough Therapy, Clinical Trials, Cybin, Hallucinogens, Identifier, mental health, N,N-Dimethyltryptamine, Psilocybin, United States Food and Drug Administration

Cybin, psychedelic therapeutics, mental health treatments, deuterated psilocybin, deuterated DMT, clinical trials, FDA Breakthrough Therapy Designation.